Top Buy
| Security | Buy | Sell | Buy (1M) ▼ | Sell (1M) | Price | Target price | Potential |
|---|---|---|---|---|---|---|---|
| Eli Lilly Corp. | 68 | 0 | 10 | 0 | €815.00 | €831.01 | 1.964% |
| Insmed Inc. | 45 | 0 | 7 | 0 | €63.50 | €76.89 | 21.079% |
| BioMarin Pharmaceutical Inc. | 26 | 0 | 6 | 0 | €75.84 | €102.62 | 35.310% |
| Pfizer Inc. | 30 | 4 | 5 | 0 | €25.77 | €41.29 | 60.215% |
| PTC Therapeutics Inc. | 17 | 9 | 5 | 0 | €28.20 | €41.46 | 47.032% |
| Alnylam Pharmace. | 48 | 1 | 5 | 1 | €222.50 | €270.99 | 21.793% |
| Regeneron Pharmaceuticals Inc. | 48 | 1 | 4 | 0 | €1,021.0 | €1,085.0 | 6.273% |
| Cytokinetics Inc. | 33 | 1 | 4 | 0 | €48.80 | €83.21 | 70.502% |
| Esperion Therapeutis.Inc. | 17 | 1 | 3 | 0 | €1.49 | €9.27 | 521.293% |
| United Therapeutics | 28 | 1 | 3 | 0 | €311.80 | €323.16 | 3.642% |
| Catalyst Pharmaceutical Partners Inc | 15 | 0 | 3 | 0 | €17.98 | €25.69 | 42.872% |
| Krystal Biotech | 19 | 0 | 3 | 0 | €167.90 | €185.58 | 10.530% |
| Neurocrine Bioscience | 44 | 0 | 3 | 0 | €108.35 | €149.47 | 37.953% |
| Verastem Inc. | 14 | 0 | 3 | 0 | €2.18 | €16.16 | 641.344% |
| Zoetis Inc. A | 23 | 1 | 3 | 0 | €170.66 | €196.17 | 14.946% |
| Intra-Cellular Therapies Inc. | 32 | 0 | 2 | 0 | €66.50 | €84.46 | 27.002% |
| Prothena Corp. plc | 13 | 0 | 2 | 0 | €18.40 | €78.70 | 327.720% |
| Adverum Biotechnologies Inc. | 10 | 0 | 2 | 0 | €1.38 | €25.32 | 1734.529% |
| Amicus Therapeutics Inc. | 9 | 0 | 2 | 0 | €10.40 | €17.63 | 69.538% |
| AbbVie Inc. | 34 | 0 | 2 | 0 | €174.48 | €180.90 | 3.681% |
| Abbott Laboratories | 20 | 0 | 2 | 0 | €102.78 | €116.25 | 13.103% |
| Codexis Inc. | 7 | 1 | 2 | 0 | €2.48 | €9.62 | 288.356% |